Navigation Links
Pharmacopeia Announces Third Quarter 2007 Financial Results
Date:11/1/2007

Pharmacopeia Advances and Expands Internal Pipeline as DARA Program Enters

Phase 2 Clinical Development and New SARM Program is Added

PRINCETON, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP) today announced results for the quarter and nine months ended September 30, 2007, and highlighted several important developments in its therapeutic programs and corporate milestones achieved since the beginning of the quarter.

During the third quarter of 2007:

-- Pharmacopeia announced the initiation of a Phase 2a hypertension

clinical trial for PS433540, an unpartnered product candidate from its

DARA program, that is both an angiotensin receptor blocker (ARB) and an

endothelin receptor antagonist (ERA). The trial was initiated less

than one year after IND submission and approximately six months ahead

of schedule.

Also during the quarter, the company announced positive results from

multiple Phase 1 clinical studies for PS433540. These Phase 1 findings

included:

-- PS433540 demonstrated its ability to block the increase in blood

pressure induced by administration of angiotensin II (AII) to

healthy volunteers. Numerous similar studies with other agents that

block the renin-angiotensin system support that this result is a

strong indication that PS433540 can be expected to lower blood

pressure in hypertensive patients. This Phase 1 study showed that

all doses of PS433540, compared with placebo, produced a

statistically significant (p<0.01) inhibition of the expected AII-

induced increase in blood pressure. Additionally, the findings

showed that the 250 mg and 500 mg doses of PS433540 were at least as

effective in blocking the AII response as irbesartan, a leading

angiotensin receptor blocker that is approved for th
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... PHILADELPHIA , April 24, 2015  Lannett Company, ... has amended and increased its five-year revolving credit facility ... includes an accordion feature that will allow the company ... an additional $30.0 million, subject to securing additional commitments ... date of the credit facility remains December 18, 2018. ...
(Date:4/24/2015)... Mass. , April 24, 2015  Blueprint ... BLU-554, a selective and potent inhibitor of fibroblast ... activity in models of hepatocellular carcinoma (HCC) that ... therapeutic candidate, BLU-554 induced complete tumor regression in ... an FGFR4-activating ligand at the highest dose levels. ...
(Date:4/23/2015)... , April 23, 2015 Once again, ... strengthening our commitment to patient safety. BeaconMedaes, ... fight against infectious disease. The next generation ... Medical gas sensors are now mounted in the assembly, ... need to open ceiling tiles potentially releasing dust spores ...
Breaking Medicine Technology:Lannett Expands Revolving Credit Facility To $120 Million 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3BeaconMedaes launches new Zone Valve Box Assembly 2
... REDWOOD CITY, Calif., Aug. 17 Cardica, Inc. (Nasdaq: ... Intuitive Surgical, Inc. have entered into a license agreement ... intellectual property, which relates to tissue cutting, stapling and ... to the license agreement, Cardica and Intuitive may also ...
... (Nasdaq: BMRN ) announced today that it ... company developing enzyme replacement therapies (ERT) for the treatment ... ZC-701, a novel fusion of insulin-like growth factor 2 ... Under the terms of the agreement, BioMarin ...
Cached Medicine Technology:Cardica and Intuitive Surgical Enter Into License Agreement 2Cardica and Intuitive Surgical Enter Into License Agreement 3BioMarin Acquires ZyStor Therapeutics, Inc. 2BioMarin Acquires ZyStor Therapeutics, Inc. 3BioMarin Acquires ZyStor Therapeutics, Inc. 4BioMarin Acquires ZyStor Therapeutics, Inc. 5
(Date:4/24/2015)... 2015 Anchor Health Administrators (Anchor), specialists ... today announced their exclusive agreement with LTC Solutions for ... Insurance distribution partner. , Anchor has more than 18 ... benefits for associations, and is currently the designated advocate ... Term Care Insurance member benefit. , “I am very ...
(Date:4/24/2015)... Olive Fertility Centre is proud to ... co-director, has been honoured for his pioneering work in ... Hope Gala. , “We are very pleased to ... has been at the forefront of fertility research and ... Executive Director of Fertile Futures--a Canadian non-profit organization that ...
(Date:4/24/2015)... With years of experience providing consumer ... to be partnered with a veterinary college where veterinary ... This partnership has brought new payment options for families ... providing an in-house payment plan for many years, the ... to increase financing options available to avoid having to ...
(Date:4/24/2015)... National Access Cannabis (NAC), ... to medical cannabis, is taking a leadership role in ... patients. , NAC is the first to back mdBriefCase ... grant, NAC will be providing 300 healthcare professionals with ... to help Canadians gain safe and responsible access to ...
(Date:4/24/2015)... Opera ” was featured on NewsWatch as part of its ... products available to consumers. Andrew Tropeano, a technology expert and ... viewers how this is the fastest way to surf the ... be in existence. But each web browser is slightly different ... Celebrating their 20th anniversary this year, Opera connects over 350 ...
Breaking Medicine News(10 mins):Health News:Olive Fertility Centre Co-founder, Dr Al Yuzpe, Recognized as a Pioneer in Fertility Preservation 2Health News:University of Missouri Veterinary Medical Teaching Hospital Teams with UGA 2Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2Health News:A Web Browser That Connects over 350 Million People was Featured on NewsWatch Television 2
... ValueOptions(R), Inc., the nation,s largest independent behavioral ... entered into an agreement with CareIntegra to provide ... its core product offerings. (Logo: ... CareIntegra and ValueOptions(R) will collaborate to develop and ...
... Va., Jan. 7 CEL-SCI Corporation (NYSE Alternext ... announced today the initiation of a definitive study of ... the long-lasting beneficial effects on animals with the disease. ... a large pharmaceutical company which is evaluating the possibility ...
... ORLEANS, Jan. 7 Jones Walker is pleased to announce ... an Order of the British Crown that has been in ... in the New Orleans office of Jones Walker, was recently ... Hamilton, a Partner in the firm,s Mobile and Washington offices, ...
... Virginia, January 7 Ekahau Inc., a leading,provider ... announced,that after a competitive bid process it was ... to provide the Ekahau Real Time,Location System (RTLS) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081014/324879-a ) , ...
... shownOAKBROOK TERRACE, Ill., Jan. 7 Even though nurses ... study published in the January 2009 issue of ... shows that nurses often are not included when ... such a hands-on role at the bedside of their ...
... Atlanta-based Billian Publishing, Inc.,owners of Billian,s HealthDATA, announced ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070925/BILLIANSLOGO ) ... founded in 1989 just as the information technology,industry ... Since then, new,and established companies have contracted with ...
Cached Medicine News:Health News:ValueOptions(R) Enters Agreement with CareIntegra to Provide Integrated Health Services 2Health News:CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine 2Health News:CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine 3Health News:Jones Walker Attorneys Named to Positions in Order of British Crown 2Health News:Ekahau Selected to Provide RTLS to University HealthSystem Consortium 2Health News:Ekahau Selected to Provide RTLS to University HealthSystem Consortium 3Health News:Study Finds Failure to Include Nurses in Process of Admitting Errors to Patients, Families 2Health News:Study Finds Failure to Include Nurses in Process of Admitting Errors to Patients, Families 3Health News:Billian Publishing, Inc. Announces Acquisition of Porter Research 2
Stainless steel construction to withstand sterilization modalities (EtO, Steris, and Sterrad) Wide angle of view...
ENDOlap™ laparoscopes provide excellent image linearity and flatness of field....
Superior imaging through a 410,000 pixel CCD, unseen color replication from a digital signal processor in the scope, and the added benefit of four way tip deflection make the TF410 a superior choice ...
The edge-to-edge clarity of the laparoscopes provides excellent image definition.Even small structures are easily recognized due to the optimal depth of focus. The outstanding optical quality provide...
Medicine Products: